Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
Gorkin
Janet U
JU
Albert Einstein College of Medicine, Bronx, NY USA.
Watson
Karol
K
Knopp
Robert H
RH
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D002995:Clofibric Acid / Q000009:adverse effects / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000178:diet therapy / Q000235:genetics / Q000628:therapy; D015444:Exercise; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006943:Hyperglycemia / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D012307:Risk Factors
D000924:Anticholesteremic Agents; D015525:Fatty Acids, Omega-3; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin; D002995:Clofibric Acid